Pictet Asset Management
TGTX icon

Pictet Asset Management’s TG Therapeutics TGTX Stock Holding History

Pictet Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58M Buy
1,747,373
+286,325
+20% +$8.53M 0.06% 286
2025
Q4 		$43.6M Sell
1,461,048
-148,503
-9% -$4.85M 0.04% 351
2025
Q3 		$58.1M Sell
1,609,551
-297,940
-16% -$9.81M 0.06% 295
2025
Q2 		$68.7M Sell
1,907,491
-489,693
-20% -$18.2M 0.07% 259
2025
Q1 		$94.5M Sell
2,397,184
-396,747
-14% -$13.3M 0.11% 210
2024
Q4 		$84.1M Sell
2,793,931
-788,652
-22% -$22.6M 0.09% 226
2024
Q3 		$83.8M Buy
3,582,583
+339,102
+10% +$7.41M 0.09% 224
2024
Q2 		$57.7M Sell
3,243,481
-83,733
-3% -$1.34M 0.07% 256
2024
Q1 		$50.6M Sell
3,327,214
-58,031
-2% -$924K 0.06% 310
2023
Q4 		$57.8M Buy
3,385,245
+2,564,842
+313% +$29.8M 0.06% 275
2023
Q3 		$6.86M Buy
+820,403
New +$11.4M 0.01% 704

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pictet Asset Management's TGTX Position: Q1 2026 in Review

Pictet Asset Management increased its TG Therapeutics (TGTX) stake by 20% in Q1 2026, buying an estimated $8.53M and bringing the position to 1,747,373 shares worth $58M. The position accounts for 0.06% of the portfolio, ranked #286.

Pictet Asset Management first reported a position in TGTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $94.5M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Pictet Asset Management held 1,747,373 shares of TG Therapeutics worth $58M as of Q1 2026.
  • Pictet Asset Management bought 286,325 TG Therapeutics shares in Q1 2026, an estimated $8.53M.
  • TG Therapeutics made up 0.06% of Pictet Asset Management's portfolio in Q1 2026, its #286 holding.
  • Pictet Asset Management first reported a position in TG Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's TG Therapeutics position peaked at $94.5M in Q1 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.